Member Info for optrade

Generally, SP has risen on RNS news, why not today? Something strange is going on.

There is no reason for SP to fall, RNS is good. Has anyone seen and large sales?

There has been a markdown for no good reason; someone wants your shares, time to top up!

SP just marked down, there is a second chance to buy now. DYOR I believe there is momentum building.

It's speculative, so don't buy more than you can afford.

There is no reason to be down 58% in a month; Met1's Management team is doing exactly what they said they would: acquiring rare earth assets and teaming up with mining companies.

(AI-generated) "Metals One (ticker: MET1) currently has up to £10 million in potential funding available through outstanding cash warrants priced at 2p, valid until September 2025. This is in addition to the £5.1 million already raised in April 2025 via prepaid warrants and a retail offer. So in total, they could have up to £15 million to deploy toward rare mineral site acquisitions and exploration.

As for government backing: Metals One is not directly government-backed, but they are strategically aligned with EU initiatives. Notably:

- They are applying for Strategic Project Status under the EU Critical Raw Materials Act for their Black Schist nickel-copper-cobalt-zinc project in Finland.

- This status could unlock enhanced access to project financing, permitting, and infrastructure support—essentially giving them a leg up without being formally state-funded.

So while they’re not government-owned or funded, they’re positioning themselves to benefit from policy-driven incentives tied to Europe’s clean energy and resource independence goals."

They are rapidly becoming a national priority, with too much dependency on China.

This is having a significant impact on the Western car industry. Met1 is busy with important acquisitions.

Lots more RNS in the pipeline :)

Well, sooner or later, the SP will pop again; You have to be in to win. I'm happy to sit back and let the very experienced management team do their job.

GL all :)

Longtimeinvestor, you are in danger of sounding like a parrot. Nobody knows what their licenses might be worth, they are working closely with EU to find local rare earth metals; if their pace of contracts is maintained, it won't be long before the next RNS. The race is on!

MET1 has agreements with at least 3 mining companies, working in 2025.

Today's RNS is only another investment /agreement with Fulcrum; no need to jump overboard or spend time on scam reports

Crazy move or not 50p or £5?

If you believe SP will stay below 10p do nothing; if you like speculative mining shares, and crazy moves fill your boots!

No response to shameless shorters? who can blame them.

Here’s the real bottom line: Metals One’s share price should already reflect the reality of its £3 billion mineral reserves.

Industry experts agree: MET1 shares are primed for an explosive upward correction—possibly reaching beyond £5 per share, from today’s price of under 10p

Metals One acquires 10% interest in NovaCore’s Red Basin Uranium Project. announced 18th July SP jumps up

Metals One now announces an investment in Fulcrum for its innovative mining technology. It's Fulcrum who has issued more shares, not MET1 as far as I can see. Looks like the MET1 sp drop is overdone.

However, with revenue expected to exceed £100M (up 30%) and approximately £337 million in cash or cash equivalents, it appears the ball is gaining strong momentum towards profitability.

Even so, the results were excellent, Better than expected, which triggered the 15% spike

For the SP to fall back today to below the result announcement creates another buying opportunity.

This is a Pfizer scientific endorsement only, I will wait for a binding commercial agreement.

In the meantime, I prefer the Valirx - Ambrose deal. It has a signed commercial contract where Ambrose commits to all funding development and patent costs

Just topped up, I expect the SP to climb again today or by tomorrow morning at the latest.

It's still a day trader's share despite having a signed deal with Melrose, which has a higher chance of producing positive cash flow than the OBD non binding announcement. It takes fewer trades of lower amounts to raise the SP, so it's a definite hold for those with fewer day traders in the future.

ValiRx–Ambrose: A Signed Licensing Agreement

- Ambrose has formally exercised its option to license VAL401, triggering a binding agreement.

- ValiRx is set to receive shares, milestone payments, and royalties, with Ambrose committed to funding development and patent costs.

- This is a contractual deal with defined financial terms, making it a clearer path to income—though still contingent on milestones.

🔬 OBD–Pfizer: Validation, Not a Commercial Deal (Yet)

- Pfizer’s recent bladder cancer trial validated OBD’s EpiSwitch biomarkers as effective indicators of immune activity.

- While this is a strong scientific endorsement, there’s no formal licensing or revenue-sharing agreement in place.

- OBD’s leadership has expressed confidence that deals will come, but it’s still in the pre-commercial phase.

🧭 Bottom Line

- ValiRx’s deal is a signed commercial agreement with income potential tied to milestones.

- OBD’s Pfizer collaboration is a promising validation, but not yet monetised through a formal deal.